ACLARUBICIN HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C42H53NO15.ClH
Molecular Weight	848.329
Optical Activity	UNSPECIFIED
Defined Stereocenters	13 / 13
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)C5=C(C=C6C(=O)C7=C(C(O)=CC=C7)C(=O)C6=C5O)[C@H]1C(=O)OC

InChI

InChIKey=KUSMIBXCRZTVML-PCCPLWKKSA-N

InChI=1S/C42H53NO15.ClH/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29;/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3;1H/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+;/m0./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C42H53NO15
Molecular Weight	811.8679
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	13 / 13
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.toku-e.com/product/aclarubicin_hydrochloride/
Curator's Comment: description was created based on several sources, including: http://www.druginfosys.com/Drug.aspx?drugCode=29&drugName=Aclarubicin%20(HCl)&type=8

Aclarubicin (INN) or aclacinomycin A is an anthracycline drug is primarily indicated in conditions like Acute non-lymphoblastic leukemia, Breast cancer, Gastric cancer, Lymphoma, Ovarian coma, Small cell lung cancer, Thyroid cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin. Aclarubicin (HCl) is used in combination with different anticancerous drugs to obtain best therapeutic results and to reduce toxicity or side effects. Aclarubicin (HCl) is administered intravenously. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA topoisomerase II 66 Target ID: CHEMBL2094255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23533247	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Small-cell lung cancer 41 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1321008	Primary	Phase II 1147	Unknown Approved Use Unknown
Thyroid cancer 17 Sources: http://www.ncbi.nlm.nih.gov/pubmed/3181249	Primary	Phase II 1147	Unknown Approved Use Unknown
Lymphoma 60 Sources: http://www.ncbi.nlm.nih.gov/pubmed/3867405	Primary	Phase II 1147	Unknown Approved Use Unknown
Gastrointestinal adenocarcinoma 2 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2206579	Primary	Phase I 438	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
In vitro antifungal activity of DNA topoisomerase inhibitors.	2012-04	21939347
Discovery, synthesis, and biological evaluation of novel SMN protein modulators.	2011-09-22	21819082
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011-07-14	21599003
Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours.	2010-07-19	20399885
Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening.	2009-03-24	19255438
Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation.	2005-12	16215684
Expression of glutathione S-transferase P1-1 in differentiating K562: role of GATA-1.	2003-11-28	14623254
Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis.	2002-12	12370496
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.	2000-05	10815900
1,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication.	2000-02	10809021
Oxidative stress involvement in chemically induced differentiation of K562 cells.	2000-01-01	10656287
Enhancement of chemosensitivity toward anticancer drugs by high expression of caspase-1 in NIH 3T3 cells.	1998-01	9491796
In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis.	1993-12	8109920
Antifungal anthracycline antibiotics, spartanamicins A and B from Micromonospora spp.	1992-11	1468980
[Torsade de pointes ventricular tachycardia in a patient with acute myelocytic leukemia].	1991-09	1942537
Inhibition by doxorubicin of human immuno-deficiency virus (HIV) infection and replication in vitro.	1987-03	2437093

Patents

Sample Use Guides

In Vivo Use Guide

25 to 100 mg/sq.meter. Maintenance, Every 3-4 Week

Route of Administration: Intravenous

In Vitro Use Guide

aclarubicin (ACR) blocked the human lymphocytes progression at G1 period at the concentrations of 100 and 200 ng/ml, but the number of dead cells was not increased.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:52:24 GMT 2025` Edited by `admin` on `Mon Mar 31 17:52:24 GMT 2025`
Record UNII	501948RI66
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ACLARUBICIN HYDROCHLORIDE

Common Name

English

ACLACINOMYCIN A HYDROCHLORIDE

Preferred Name

English

ACLARUBICIN HYDROCHLORIDE [MART.]

Common Name

English

Aclarubicin hydrochloride [WHO-DD]

Common Name

English

ACLARUBICIN HYDROCHLORIDE [JAN]

Common Name

English

ACLARUBICIN HCL

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C987